Artal Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Artal Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-500,000	Closed	-$56.1M	–	156
2020 Q2	$56.1M	Buy	+500,000	New	+$53.1M	1.57%	15
2018 Q2	–	Sell	-150,000	Closed	-$16.7M	–	122
2018 Q1	$16.7M	Sell	150,000 -500,000	-77%	-$59.8M	0.21%	36
2017 Q4	$77.7M	Buy	+650,000	New	+$79.2M	1.17%	9
2017 Q3	–	Sell	-20,900	Closed	-$2.54M	–	123
2017 Q2	$2.54M	Buy	+20,900	New	+$2.43M	0.04%	89
2017 Q1	–	Sell	-350,000	Closed	-$42.8M	–	112
2016 Q4	$42.8M	Buy	350,000 +100,000	+40%	+$12.2M	0.95%	12
2016 Q3	$30.6M	Buy	+250,000	New	+$32.2M	0.61%	19

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's ALXN Position: Q3 2017 in Review

Artal Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 100,000 shares — an estimated $12.2M sold.

Artal Group first reported a position in ALXN in Q4 2016 and held it in 3 quarters. The position peaked at $24.5M in Q4 2016. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

Artal Group reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Artal Group sold 100,000 Alexion Pharmaceuticals shares in Q3 2017, an estimated $12.2M.
Artal Group first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 3 quarters.
Artal Group's Alexion Pharmaceuticals position peaked at $24.5M in Q4 2016.
595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.